MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5664/jcsm.11682

Медицинская библиотека · Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025

Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review.

Sevencan Beyza, Steenackers Nele, van Laar Amar Daniël Emanuel, Pazmiño Lucio Sofía, Buyse Bertien, Kalkanis Alexandros, Testelmans Dries, Van der Schueren Bart

СтатьяОбзорПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

STUDY

OBJECTIVES

To assess the effectiveness of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists in the treatment of obstructive sleep apnea.

METHODS

A comprehensive literature search was performed across multiple medical databases, including Embase, Medline, and Cochrane to look for English articles on interventions with SGLT2 inhibitors, GLP-1, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists in people living with sleep apnea and overweight or obesity.

RESULTS

Emerging evidence indicates that SGLT2 inhibitors, GLP-1, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are beneficial for treating obesity in combination with sleep apnea. Although these medications have shown promise in weight reduction, with GLP-1 receptor agonists slightly outperforming SGLT2 inhibitors, their effect on sleep apnea extends beyond mere weight loss. Preliminary studies suggest a beneficial role in obstructive sleep apnea management with reductions in the apnea-hypopnea index and potential improvements in other sleep-related outcomes.

CONCLUSIONS

There is a need for more therapeutic options to treat sleep apnea as adherence with current treatment options remains a struggle for many patients. According to preliminary research, SGLT2 inhibitors, GLP-1 and dual gastric inhibitory polypeptide/GLP-1 receptor agonists are promising candidates because they do show beneficial effects on apnea-hypopnia index and weight. Nevertheless, large-scale clinical trials are needed to assess their clinical potential and risk balance in more detail.

CITATION: Sevencan B, Steenackers N, van Laar ADE, et al. Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review. J Clin Sleep Med. 2025;21(8):1433-1444.

Для цитирования: Sevencan Beyza, Steenackers Nele, van Laar Amar Daniël Emanuel, Pazmiño Lucio Sofía, Buyse Bertien, Kalkanis Alexandros, Testelmans Dries, Van der Schueren Bart. Evaluating the potential of metabolic drugs in obstructive sleep apnea and obesity: a narrative review.. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2025. DOI: 10.5664/jcsm.11682.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.